1202920-72-6

Basic information

• Product Name: 4-amino-5-[2,4-bis(benzyloxy)-5-isopropylphenyl]isoxazole-3-carboxylic acid ethylamide
• Synonyms: 4-amino-5-[2,4-bis(benzyloxy)-5-isopropylphenyl]isoxazole-3-carboxylic acid ethylamide
• CAS NO: 1202920-72-6
• Molecular Weight: 485.583
• Mol File: 1202920-72-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-amino-5-[2,4-bis(benzyloxy)-5-isopropylphenyl]isoxazole-3-carboxylic acid ethylamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-5-[2,4-bis(benzyloxy)-5-isopropylphenyl]isoxazole-3-carboxylic acid ethylamide(1202920-72-6)
• EPA Substance Registry System: 4-amino-5-[2,4-bis(benzyloxy)-5-isopropylphenyl]isoxazole-3-carboxylic acid ethylamide(1202920-72-6)

Safety Data

• Hazardous Substances Data: 1202920-72-6(Hazardous Substances Data)

Upstream product

• 1202920-71-5 5-[2,4-bis(benzyloxy)-5-isopropylphenyl]-4-nitroisoxazole-3-carboxylic acid ethylamide 
• 747414-21-7 5-(2,4-bis(benzyloxy)-5-isopropylphenyl)isoxazole-3-carboxylic acid ethylamide 

Downstream Products

• 1350722-60-9 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-dimethylaminobenzoylamino)isoxazole-3-carboxylic acid ethylamide 
• 1350722-80-3 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[(furan-2-carbonyl)amino]isoxazole-3-carboxylic acid ethylamide 
• 1350722-69-8 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[(5-phenylisoxazole-3-carbonyl)amino]isoxazole-3-carboxylic acid ethylamide 
• 1202921-50-3 1H-indole-6-carboxylic acid [5-(2,4-dihydroxy-5-isopropyl-phenyl)-3-ethylcarbamoylisoxazol-4-yl]amide 
• 1350723-14-6 5-[2,4-bis(benzyloxy)-5-isopropylphenyl]-4-[(4-trans-hydroxymethyl-cyclohexylcarbonyl)amino]isoxazole-3-carboxylic acid ethylamide 
• 1202920-69-1 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-methoxybenzoylamino)isoxazole-3-carboxylic acid ethylamide 
• 1202920-84-0 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[(3-methylthiophene-2-carbonyl)amino]isoxazole-3-carboxylic acid ethylamide 
• 1350722-84-7 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-[(4-trans-hydroxy-cyclohexanecarbonyl)amino]isoxazole-3-carboxylic acid ethylamide 
• 1350722-85-8 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-[(4-cis-hydroxy-cyclohexanecarbonyl)amino]isoxazole-3-carboxylic acid ethylamide 
• 1350722-86-9 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-[(4-cis-hydroxymethyl-cyclohexanecarbonyl)amino]isoxazole-3-carboxylic acid ethylamide 
• 1350722-87-0 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-[(4-trans-hydroxymethyl-cyclohexylcarbonyl)amino]isoxazole-3-carboxylic acid ethylamide 
• 1350723-18-0 5-[2,4-bis(benzyloxy)-5-isopropylphenyl]-4-[(trans-4-morpholin-4-yl-cyclohexanecarbonyl)amino]isoxazole-3-carboxylic acid ethylamide hydrochloride 
• 1350722-66-5 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(5-ethylisoxazole-3-carbonyl)aminoisoxazole-3-carboxylic acid ethylamide 
• 1350722-72-3 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[(2,4-dimethylthiazole-5-carbonyl)amino]isoxazole-3-carboxylic acid ethylamide 

Relevant articles and documents

Exploring in vitro and in vivo Hsp90 inhibitors activity against human protozoan parasites

A set of compounds, previously selected as potent Hsp90α inhibitors, has been studied on a panel of human parasites. 5-Aryl-3,4-isoxazolediamide derivatives (1) were active against two protozoa, Trypanosoma brucei rhodesiense and Plasmodium falciparum, with a good tolerability toward cytotoxicity on non-malignant L6 rat myoblast cell line, unlike the 1,5-diaryl,4-carboxamides-1,2,3-triazole derivatives (2) which, while showing a single-digit nM range activity against the same protozoa, were also highly cytotoxic on L6 cells. In a subsequent in vivo study, two isoxazolediamide derivatives, 1a and 1b, were very efficacious on the sleeping sickness-causing agent with a clear parasitaemia during treatment. These data, however, showed that not all protozoa are sensitive to Hsp90 inhibitors, as well as not all Hsp90 inhibitors are equally active on parasites.

5-PHENYL-ISOXAZOLE-3-CARBOXAMIDES MODULATING HSP90 WITH ANTITUMORAL ACTIVITIES

The present invention relates to formula I compounds having antitumoural activities through, as one possible biological target, the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The invention includes the use of such compounds in medicine,